INNOCAN PHARMA CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.28 CAD | 0.00% |
|
-5.08% | -9.68% |
| Sales 2022 | 2.56 3.5 | Sales 2023 | 13.66 18.67 | Capitalization | 62.67M 85.66M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -4.1M | Net income 2023 | -4M -5.47M | EV / Sales 2022 | 15,473,821 x |
| Net cash position 2022 | 4.91 6.72 | Net cash position 2023 | 3.85 5.27 | EV / Sales 2023 | 4,588,686 x |
| P/E ratio 2022 |
-10.5
x | P/E ratio 2023 |
-12.8
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 75.75% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 week | -5.08% | ||
| Current month | -1.75% | ||
| 1 month | -3.45% | ||
| 3 months | -9.68% | ||
| 6 months | -9.68% | ||
| Current year | -9.68% |
1 week
0.27
0.29
1 month
0.240.33
Current year
0.240.34
1 year
0.180.52
3 years
0.181.65
5 years
0.051.65
10 years
0.051.65
| Managers | Title | Age | Since |
|---|---|---|---|
Nir Avram
FOU | Founder | 71 | - |
Iris Bincovich
FOU | Founder | - | 18-05-30 |
Nelson Halpern
DFI | Director of Finance/CFO | - | 19-02-19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Bloch
BRD | Director/Board Member | 64 | 20-01-21 |
| Chairman | 60 | 14-05-31 | |
Iris Bincovich
FOU | Founder | - | 18-05-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 0.28 | 0.00% | 26,200 |
| 24-06-05 | 0.28 | 0.00% | 4,000 |
| 24-06-04 | 0.28 | 0.00% | 500 |
| 24-06-03 | 0.28 | -1.75% | 43,840 |
| 24-05-31 | 0.285 | -3.39% | 15,500 |
Delayed Quote Canadian Securities Exchange, June 06, 2024 at 01:48 pm EDT
More quotes
Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
Sector
Pharmaceuticals
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -9.68% | 57.41M | |
| +43.64% | 754B | |
| +39.42% | 630B | |
| -6.58% | 352B | |
| +19.72% | 331B | |
| +8.78% | 298B | |
| +11.92% | 217B | |
| -2.62% | 216B | |
| +0.03% | 163B | |
| +6.13% | 164B |
- Stock Market
- Equities
- INNO Stock
